retina

Treatment for geographic atrophy lacks efficacy in Phase 2 studyIn a placebo-controlled, dose-finding, proof-of-concept study conducted in patients with geographic atrophy secondary to age-related macular degeneration, an anti-amyloid β monoclonal antibody (GSK933776, GlaxoSmithKline) was safe and well-tolerated, but did not meet primary or secondary efficacy endpoints.
TREX-AMD trial finds visual gains from treat-and-extend vs. monthlyTreat-and-extend approach for neovascular AMD leads to beneficial results in 2-year clinical trial.
The poor man’s red/green testOne morning, as a few faculty members were squeezing in a workout before work, the topic arose of how to use the red-green (Duochrome) test most efficiently in clinic.
Using OCT with your diabetes patientsOCT is one of the best way to assess patients for the presence of diabetic macular edema (DME)
Nailing intravitreal implant injectionsTreating diabetic macular edema (DME) has evolved from the ETDRS-style focal/grid laser being the standard of care since 1985 to the modern era of pharmacotherapy—with anti-vascular endothelial growth factor (VEGF) injections now taking center stage as primary treatment for most patients.
Enhancing retinal surgery with 27-gauge instrumentationThe use of 27-gauge instrumentation provides several surgical advantages compared with larger tools in retinal surgery, particularly in difficult cases.
Transplantable 3-D retinasAIVITA Biomedical has successfully engineered a three-dimensional transplantable retina construct and demonstrated connectivity and conductivity in an animal model of retinal degeneration.
New concepts about macular edema emerge from modern imaging studiesVolume-rendered optical coherence tomography (OCT) imaging allows new insight into retinal vascular flow and morphological changes in eyes with macular edema (ME), and the information obtained is the basis for new ideas about the pathogenesis of ME and therapeutic intervention, according to Richard F. Spaide, MD, Vitreous Retina Macula Consultants of New York.
Findings reaffirm ocriplasmin success for symptomatic VMA over long termResults of a 2-year phase IIIb study include findings consistent with earlier information about treatment success with ocriplasmin injection for symptomatic vitreomacular adhesion and new information about efficacy and safety over the longer term.
Data support adding suprachoroidal injection to anti-VEGF for RVOResults from the phase II TANZANITE clinical trial support further investigation of adding suprachoroidal triamcinolone acetonide to anti-vascular endothelial growth factor therapy for treatment-naïve retinal vein occlusion.